Show Summary Details
Page of

Clozapine for Treatment-Resistant Schizophrenia 

Clozapine for Treatment-Resistant Schizophrenia
Clozapine for Treatment-Resistant Schizophrenia

Chadrick Lane

, and Vinod H. Srihari

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 January 2021

This chapter provides a summary of a landmark study on the pharmacologic management of treatment-resistant schizophrenia. This clinical trial, conducted by Kane and colleagues, asks whether clozapine is an effective option in the care of patients with treatment-resistant schizophrenia who have not responded to past trials of first-generation antipsychotics. To answer this question, the chapter reviews the basics of the study, including funding sources, study location, inclusion and exclusion criteria, number of participants, research design, interventions, follow-up, endpoints, results, criticisms, and limitations. The chapter briefly reviews other relevant studies and information, discusses implications, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.